Thymic Organoid Generation from Pluripotent Stem Cells
Solution Overview
Problem
Adoptive cell therapy using T cell lineage cells for cancer treatment faces challenges in producing cells in vitro or ex vivo, requiring improved methods and materials for preparing these cells.
Innovation Solution
A method for preparing thymic organoids in vitro by differentiating pluripotent stem cells into thymic epithelial cells, which are then used to generate thymic emigrant cells for treatment, involving a series of specific differentiation steps without co-culturing with mesenchyme or stromal cells, and administering these cells to treat or prevent conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional methods are used to produce T cell lineage cells in vitro or ex vivo, then T cells can be generated for adoptive cell therapy, but the production process is challenging and complex
Solution Approach 1:
The patent segments the complex thymus organoid into distinct functional regions (cortex and medulla) with specific cell types (cTECs, mTECs, dendritic cells, etc.), allowing independent differentiation and culture of each segment. This enables simplified production protocols for each cell type while maintaining overall organoid functionality, directly addressing the complexity challenge.
Solution Approach 2:
The patent employs preliminary differentiation of pluripotent stem cells into definitive endoderm and third pharyngeal pouch endoderm before generating thymic epithelial cells. This staged approach breaks down the complex differentiation pathway into manageable steps, improving ease of manufacture by allowing optimization of each stage independently.
2Reliability
If co-culturing with mesenchyme or stromal cells is used, then thymic organoid development may be enhanced, but the method becomes more complex and requires additional cell types
Solution Approach 1:
The patent extracts and eliminates the requirement for mesenchymal or stromal cell co-culturing from the thymic organoid formation process. By using defined small molecule factors (Wnt3a, BMP4, FGF7, retinoic acid, IWR-1) to drive differentiation, the method achieves reliable organoid formation without needing additional cell types, thus reducing system complexity while maintaining reliability.
Solution Approach 2:
The patent replaces the mechanical/co-cultural approach (requiring physical co-culturing with mesenchymal cells) with a biochemical approach using defined small molecule factors. This substitution eliminates the need for complex multi-cell type cultures while maintaining reliable thymic organoid formation through molecular signaling pathways.
3Productivity
If a multi-step differentiation protocol is used, then thymic organoids can be generated from pluripotent stem cells, but the process time and steps increase
Solution Approach 1:
The patent optimizes culture conditions by changing key parameters such as using defined small molecule factors (Wnt3a, BMP4, FGF7), controlling oxygen levels (5% O2), adjusting pH (7.4), and using specific media compositions (TEC expansion medium). These parameter optimizations accelerate differentiation rates and improve productivity while managing process time through controlled environmental conditions.
Data Source
AI summary
Disclosed are methods of preparing thymic organoids according to embodiments of the invention. Also disclosed are methods of preparing thymic emigrant cells in vitro, according to embodiments of the invention. Also disclosed are methods of treating or preventing a condition in a mammal, e g., cancer.